ENYO Pharma raised €32 million in its Series C financing with a new €6 million investment from Vesalius Biocapital IV to support clinical studies and research in severe kidney diseases.
ENYO Pharma raised €32 million in its Series C financing with a new €6 million investment from Vesalius Biocapital IV to support clinical studies and research in severe kidney diseases.
06/12/25, 11:13 AM
Location
lyonMoney raised
€32 million
Industry
biotechnology
Round Type
series c
Investors
Vesalius Biocapital Iv
ENYO Pharma announced the completion of its Series C financing round with a total raise of €32 million, including a new investment of €6 million from Vesalius Biocapital IV. The funds will support two additional clinical studies and expand preclinical research efforts. With this funding, ENYO aims to further its research in severe kidney diseases, particularly in Alport syndrome. The company anticipates topline results from its ALPESTRIA-1 Phase 2 trial by Q4 2025.
Company Info
Location
lyon, auvergne rhône alpes, france
Additional Info
ENYO Pharma is developing innovative therapeutics based on fibrolytic and anti-inflammatory properties for diseases with impaired kidney function.
The company is conducting Phase 2 trials with its lead compound Vonafexor in Chronic Kidney Diseases (CKD) and rare kidney disease such as Alport syndrome, and liver diseases (such as Non-Alcoholic SteatoHepatitis, NASH).